一线化疗治疗眼附属器MALT淋巴瘤临床疗效

本研究分析一线化疗治疗眼附属器黏膜相关淋巴组织结外边缘区B细胞淋巴瘤(MALT)的临床疗效。回顾性分析8例眼附属器MALT淋巴瘤患者的临床资料。给予3例ⅠE期患者COP/CHOP方案治疗。给予5例Ⅳ期患者COP/CHOP联合利妥昔单克隆抗体。结果表明:完全缓解(CR)加部分缓解(PR)的有效率100%,3例ⅠE期患者获得PR,5例Ⅳ期患者获CR,中位随访时间21个月,患者疾病无进展,3例ⅠE期患者仍持续PR,5例Ⅳ期患者持续CR。结论:眼附属器MALT淋巴瘤呈惰性临床过程,化疗安全有效,联合利妥昔单克隆抗体方案能明显提高缓解率,可以作为一线治疗方案。

Efficacy of chemotherapy as a first-line treatment in patients with ocular adnexal MALT lymphoma

The aim of this study was to analyze the efficacy of first-line chemotherapy in treating patients with ocular adnexal etranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT). Eight consecutive newly diagnosed ocular adnexal MALT lymphoma patients were treated with chemotherapy, in which 3 patients in stage IE were treated with a combination of cyclophosphamide, vincristine and prednisolone (COP) or cyclophosphamide, adriamycin, vincristine, and prednisolone (CHOP), 5 patients in stage IV were treated with COP/CHOP in combination with rituximab. The results showed that chemotherapy resulted in an overall response rate of 100%, 3 patients in stage IE were in partial remission (PR), 5 patients in stage IV were in complete remission (CR). After a median follow-up of 21 months, 3 patients in stage IE were still in PR status, 5 patients in stage IV were still in CR status, and no relapses or disease progression were observed. It is concluded that the first-line chemotherapy has been confirmed to be effective and well tolerated in patients with localized ocular adnexal MALT lymphoma. Rituximab combined with chemotherapy can increase remission rate, it is feasible option as first-line treatment for ocular adnexal MALT lymphoma.